Crucell suspends Aerugen development
Dutch biotechnology company Crucell NV says that it has suspended development of Aerugen, its vaccine candidate for the prevention of Pseudomonas aeruginosa, after it failed to demonstrate efficacy in Phase III trials.
Cystic fibrosis results from a genetic abnormality which causes the secretion of an abnormally thick viscous mucus that builds up in the lungs. This sticky layer increases the risk of serious life-threatening pseudomonas infection.
The firm said that the Phase III program, which was a double-blind, randomized examination of the product's ability to prevent Pseudomonas aeruginosa colonization in 476 cystic fibrosis patients, could not reproduce the treatment efficacy that was observed in a previous trial. As a result, the company said that it has decided to stop further development of the product.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze